Skip to main content
SpringerLink
Log in

Endometrial and Cervical Cancers

  • Chapter
  • First Online:
Practical Medical Oncology Textbook

Part of the book series: UNIPA Springer Series ((USS))

  • 3340 Accesses

Abstract

Uterine corpus and cervical cancers are showing, in the last decades, increasing incidence and mortality in industrialized and developing countries, respectively; on the other hand, innovative therapeutic strategies are emerging for the management of advanced gynecological malignancies. Risk factors and predisposing conditions are widely and continually studied; thus, prevention, through lifestyle correction and/or validated screening tests, could represent a promising tool to diagnose earlier and reduce mortality of uterine cancers. Herein, management of endometrial and cervical tumors from diagnosis to commonly applied standards of care and experimental frontiers are depicted so as to profile gynecological cancers in personalized medicine era.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

    Article  PubMed  Google Scholar 

  2. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.

    Article  CAS  PubMed  Google Scholar 

  3. Endometrial cancer statistics Available online.: https://www.wcrf.org/dietandcancer/cancer-trends/endometrial-cancer-statistics.

  4. Cook LS, Weiss NS, Doherty JA, Chen C. Endometrial Cancer: Oxford University Press; 2006. ISBN 978-0-19-986506-2.

    Google Scholar 

  5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  PubMed  Google Scholar 

  6. Endometrial Cancer Treatment (PDQ®)–Health Professional Version Available online.: https://www.cancer.gov/types/uterine/hp/endometrial-treatment-pdq.

  7. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.

    Article  PubMed  Google Scholar 

  8. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2010;19:3119–30.

    Article  CAS  Google Scholar 

  9. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Giugliano D. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014;45:28–36.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang Y, Liu H, Yang S, Zhang J, Qian L, Chen X. Overweight, obesity and endometrial cancer risk: results from a systematic review and meta-analysis. Int J Biol Markers. 2014;29:e21–9.

    Article  PubMed  Google Scholar 

  11. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.

    Article  CAS  PubMed  Google Scholar 

  12. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S, La Vecchia C. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22:884–9.

    Article  CAS  PubMed  Google Scholar 

  13. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Consumption of animal foods and endometrial cancer risk: a systematic literature review and meta-analysis. Cancer Causes Control. 2007;18:967–88.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhao J, Lyu C, Gao J, Du L, Shan B, Zhang H, Wang H-Y, Gao Y. Dietary fat intake and endometrial cancer risk. Medicine (Baltimore). 2016;95:e4121.

    Article  CAS  PubMed  Google Scholar 

  15. Zucchetto A, Serraino D, Polesel J, Negri E, De Paoli A, Dal Maso L, Montella M, La Vecchia C, Franceschi S, Talamini R. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev. 2009;18:316–21.

    Article  PubMed  Google Scholar 

  16. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748–58.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Peiretti M, Colombo N. Sex cord-stromal tumors of the ovary. In: Ayhan A, Reed N, Gultekin M, Dursun P, editors. Textbook of gynaecological oncology: Gunes Publishing; 2012. ISBN 978-975-277-387-5.

    Google Scholar 

  18. Humans, I.W.G. on the E. of C.R. to Hormonal contraception and post-menopausal hormonal therapy; International Agency for Research on Cancer, 1999.

    Google Scholar 

  19. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer (review). Oncol Lett. 2015;9:1495–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer. 1996;32A:1464–76.

    Article  CAS  PubMed  Google Scholar 

  21. Kim HS, Jeon YT, Kim YB. The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients. J Gynecol Oncol. 2008;19:256–60.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.

    Article  CAS  PubMed  Google Scholar 

  23. Lancaster JM, Powell CB, Chen L-M, Richardson DL. SGO Clinical Practice Committee Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136:3–7.

    Article  PubMed  Google Scholar 

  24. Friberg E, Orsini N, Mantzoros CS, Wolk A. Coffee drinking and risk of endometrial cancer – a population-based cohort study. Int J Cancer. 2009;125:2413–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer. 2010;17:R263–71.

    Article  CAS  PubMed  Google Scholar 

  26. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009:CD007245.

    Google Scholar 

  27. Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N. Oral and intrauterine progestogens for atypical endometrial hyperplasia. Cochrane Database Syst Rev. 2018;12:CD009458.

    PubMed  Google Scholar 

  28. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2014;142:83–9.

    Article  CAS  PubMed  Google Scholar 

  29. Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009;114:128–34.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Russo A, Incorvaia L, Malapelle U, et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBIOC-SIF italian scientific societies [published online ahead of print, 2021 Aug 6]. Crit Rev Oncol Hematol. 2021;103436. https://doi.org/10.1016/j.critrevonc.2021.103436.

  31. Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, Parry S, Hopper JL, Haile R, Jenkins MA. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer. 2010;127:2678–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD, Young JP, Rosty C, Leggett B, Giles GG, Goldblatt J, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013;105:274–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16:14–22.

    Article  PubMed  Google Scholar 

  34. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen L-M, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159–62.

    Article  PubMed  Google Scholar 

  35. Bonnet D, Selves J, Toulas C, Danjoux M, Duffas JP, Portier G, Kirzin S, Ghouti L, Carrère N, Suc B, et al. Simplified identification of Lynch syndrome: a prospective, multicenter study. Dig Liver Dis. 2012;44:515–22.

    Article  PubMed  Google Scholar 

  36. Manchanda R, Saridogan E, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Side L, Gessler S, Jacobs I, et al. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet. 2012;286:1555–62.

    Article  PubMed  Google Scholar 

  37. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2012;62:129–42.

    Article  PubMed  Google Scholar 

  38. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011;29:2247–52.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.

    Article  CAS  PubMed  Google Scholar 

  40. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.

    Article  Google Scholar 

  41. Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22:4215–24.

    Article  CAS  PubMed  Google Scholar 

  42. Soslow RA, Bissonnette JP, Wilton A, Ferguson SE, Alektiar KM, Duska LR, Oliva E. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol. 2007;31:979–87.

    Article  PubMed  Google Scholar 

  43. D’Angelo E, Prat J. Pathology of mixed Müllerian tumours. Best Pract Res Clin Obstet Gynaecol. 2011;25:705–18.

    Article  PubMed  Google Scholar 

  44. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw. 2009;7:550–6.

    Article  CAS  PubMed  Google Scholar 

  45. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23:781–9.

    Article  CAS  PubMed  Google Scholar 

  46. Epstein E, Van Holsbeke C, Mascilini F, Måsbäck A, Kannisto P, Ameye L, Fischerova D, Zannoni G, Vellone V, Timmerman D, et al. Gray-scale and color Doppler ultrasound characteristics of endometrial cancer in relation to stage, grade and tumor size. Ultrasound Obstet Gynecol. 2011;38:586–93.

    Article  CAS  PubMed  Google Scholar 

  47. Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, Gupta JK, Bakour SH, van den Bosch T, van Doorn HC, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:160–7.

    Article  PubMed  Google Scholar 

  48. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288:1610–21.

    Article  PubMed  Google Scholar 

  49. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.

    Article  PubMed  Google Scholar 

  50. Doll KM, Tseng J, Denslow SA, Fader AN, Gehrig PA. High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol. 2014;132:44–9.

    Article  PubMed  Google Scholar 

  51. Schink JC, Lurain JR, Wallemark CB, Chmiel JS. Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis. Obstet Gynecol. 1987;70:216–9.

    CAS  PubMed  Google Scholar 

  52. Benedetti Panici P, Basile S, Salerno MG, Di Donato V, Marchetti C, Perniola G, Palagiano A, Perutelli A, Maneschi F, Lissoni AA, et al. Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. Am J Obstet Gynecol. 2014;210:363.e1–363.e10.

    Article  PubMed  Google Scholar 

  53. Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017;28:e2.

    Article  PubMed  Google Scholar 

  54. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118:14–8.

    Article  PubMed  Google Scholar 

  55. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008;9:297–303.

    Article  PubMed  Google Scholar 

  56. Eddib A, Danakas A, Hughes S, Erk M, Michalik C, Narayanan MS, Krovi V, Singhal P. Influence of morbid obesity on surgical outcomes in robotic-assisted gynecologic surgery. J Gynecol Surg. 2014;30:81–6.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Shah CA, Beck T, Liao JB, Giannakopoulos NV, Veljovich D, Paley P. Surgical and oncologic outcomes after robotic radical hysterectomy as compared to open radical hysterectomy in the treatment of early cervical cancer. J Gynecol Oncol. 2017;28:e82.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Janda M, Gebski V, Davies LC, Forder P, Brand A, Hogg R, Jobling TW, Land R, Manolitsas T, Nascimento M, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA. 2017;317:1224–33.

    Article  PubMed  Google Scholar 

  59. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Barakat R, Pearl ML, Sharma SK. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group LAP2 study. J Clin Oncol. 2012;30:695–700114.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Susini T, Massi G, Amunni G, Carriero C, Marchionni M, Taddei G, Scarselli G. Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. Gynecol Oncol. 2005;96:362–7.

    Article  PubMed  Google Scholar 

  61. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–72.

    Article  PubMed  Google Scholar 

  62. ASTEC study group, Kitchener H, Swart AMC, Qian Q, Amos C, Parmar MKB. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36.

    Article  Google Scholar 

  63. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.

    Article  PubMed  Google Scholar 

  64. Geppert B, Lönnerfors C, Bollino M, Persson J. Sentinel lymph node biopsy in endometrial cancer-feasibility, safety and lymphatic complications. Gynecol Oncol. 2018;148:491–8.

    Article  PubMed  Google Scholar 

  65. Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Rouzier R, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol. 2011;12:469–76.

    Article  PubMed  Google Scholar 

  66. Bendifallah S, Canlorbe G, Raimond E, Hudry D, Coutant C, Graesslin O, Touboul C, Huguet F, Cortez A, Daraï E, et al. A clue towards improving the European Society for Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion. Br J Cancer. 2014;110:2640–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Creutzberg CL, Nout RA, Lybeert MLM, Warlam-Rodenhuis CC, Jobsen JJ, Mens J-WM, Lutgens LCHW, Pras E, van de Poll-Franse LV, van Putten WLJ, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:E631–8.

    Article  PubMed  Google Scholar 

  68. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D’Amico R, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20:1273–85.

    Article  PubMed  PubMed Central  Google Scholar 

  69. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–309.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Creutzberg CL, Leon-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Singh N, Pollock P, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on adjuvant therapy. In: Proceedings of the annals of oncology, vol. 30: Oxford University Press; 2019. p. 899–900.

    Google Scholar 

  71. DeLeon MC, Ammakkanavar NR, Matei D. Adjuvant therapy for endometrial cancer. J Gynecol Oncol. 2014;25:136–47.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Hori K, Nishio S, Ushijima K, Kasamatsu Y, Kondo E, Takehara K, Kakubari R, Ito K. A phase II, open labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine corpus cancer: KCOGG1303 study. JCO. 2019;37:5584.

    Article  Google Scholar 

  73. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22:2159–66.

    Article  CAS  PubMed  Google Scholar 

  74. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, Green JA. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409–20.

    Article  CAS  PubMed  Google Scholar 

  75. Makker V, Hensley ML, Zhou Q, Iasonos A, Aghajanian CA. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. Int J Gynecol Cancer. 2013;23:929–34.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Gynecologic Oncology Group study Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10–4.

    Article  CAS  PubMed  Google Scholar 

  77. Mileshkin L, Edmondson R, O’Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial - ANZGOG 0903. Gynecol Oncol. 2019;154:29–37.

    Article  CAS  PubMed  Google Scholar 

  78. Colon-Otero G, Weroha SJ, Zanfagnin V, Foster NR, Asmus E, Wahner Hendrickson AE, Jatoi A, Block MS, Langstraat CL, Glaser GE, et al. Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers. JCO. 2019;37:5510.

    Article  Google Scholar 

  79. Huh WK, Straughn JM, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, Gold MA, McMeekin DS, Modesitt S, Cooper AL, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 2007;17:886–9.

    Article  CAS  PubMed  Google Scholar 

  80. Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer - Full Text View - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT00492778. Accessed on 20 Jan 2020.

  81. Oza AM, Elit L, Tsao M-S, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29:3278–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, Cheng J, Li X, Campbell K, Dodion P, et al. Randomized phase II trial of Ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33:3576–82.

    Article  CAS  PubMed  Google Scholar 

  83. Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32:403–41354.

    Article  CAS  PubMed  Google Scholar 

  84. Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer. 2012;107:1869–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73:539–49.

    Article  CAS  PubMed  Google Scholar 

  86. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O’Malley DM, Stuckey A, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018;150:274–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C, Pisano C, Lapresa MT, Savarese A, Tagliaferri P, et al. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - a randomized phase II trial. Gynecol Oncol. 2019;155:406–12.

    Article  CAS  PubMed  Google Scholar 

  89. Study Of Nintedanib compared to chemotherapy in patients with recurrent clear cell carcinoma of the ovary or endometrium - full text view - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT02866370.

  90. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D’Andrea AD, Wu CJ, et al. Association of Polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319–23.

    Article  PubMed  Google Scholar 

  91. Chung HC, Ros W, Delord J-P, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, et al. Efficacy and safety of Pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470–8.

    Article  CAS  PubMed  Google Scholar 

  92. Antill YC, Kok PS, Robledo K, Barnes E, Friedlander M, Baron-Hay SE, Shannon CM, Coward J, Beale PJ, Goss G, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). JCO. 2019;37:5501.

    Article  Google Scholar 

  93. A phase 1 dose escalation and cohort expansion study of TSR-042, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors - full text view - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT02715284

  94. Pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer - full text view - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT03276013.

  95. Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:711–8.

    Article  CAS  PubMed  Google Scholar 

  96. Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000–309 Per Merck Standard Convention [KEYNOTE-775]) - Full Text View - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT03517449.

  97. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 2005;65:11597–604.

    Article  CAS  PubMed  Google Scholar 

  98. Chan N, Bristow RG. “Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res. 2010;16:4553–60.

    Article  CAS  PubMed  Google Scholar 

  99. Mackay H, Rimel B, Bender D. NRG GY012: a randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer. JCO. 2019;37:TPS5609–TPS5609.

    Article  Google Scholar 

  100. Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams SF. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015;3:1257–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer - Full Text View - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT03951415.

  102. Salani R, Backes FJ, Fung MFK, Holschneider CH, Parker LP, Bristow RE, Goff BA. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204:466–78.

    Article  PubMed  Google Scholar 

  103. Lajer H, Jensen MB, Kilsmark J, Albæk J, Svane D, Mirza MR, Geertsen PF, Reerman D, Hansen K, Milter MC, et al. The value of gynecologic cancer follow-up: evidence-based ignorance? Int J Gynecol Cancer. 2010;20:1307–20.

    PubMed  Google Scholar 

  104. Trial between two follow up regimens with different test intensity in endometrial cancer treated patients - full text view - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT00916708.

  105. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  106. Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos K, Katalinic A, Langseth H, et al. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. Eur J Cancer. 2015;51:2191–205.

    Article  PubMed  Google Scholar 

  107. Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. ESMO guidelines committee cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv72–83.

    Article  CAS  PubMed  Google Scholar 

  108. Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses. 2017;9:229.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Berrington de González A, Green J. International Collaboration of Epidemiological Studies of Cervical Cancer Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885–91.

    Article  Google Scholar 

  110. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609–21.

    Article  Google Scholar 

  111. Dugué P-A, Rebolj M, Garred P, Lynge E. Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther. 2013;13:29–42.

    Article  PubMed  Google Scholar 

  112. Hammer A, Rositch A, Qeadan F, Gravitt PE, Blaakaer J. Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis. Int J Cancer. 2016;138:2795–803.

    Article  CAS  PubMed  Google Scholar 

  113. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927–35.

    Article  CAS  PubMed  Google Scholar 

  114. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol. 2008;5:24–31.

    Article  CAS  PubMed  Google Scholar 

  115. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136:189–97.

    Article  PubMed  Google Scholar 

  116. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.

    Article  PubMed  Google Scholar 

  117. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW, Kemper AR, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320:674–86.

    Article  Google Scholar 

  118. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.

    Article  PubMed  Google Scholar 

  119. Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow S-N, Kitchener HC, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015;22:361–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.

    Article  Google Scholar 

  121. Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli URR, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018;36:4783–91.

    Article  PubMed  Google Scholar 

  122. Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial. J Natl Cancer Inst. 2018;110:205.

    Article  CAS  PubMed  Google Scholar 

  123. Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Centers for Disease Control and Prevention (CDC) use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4.

    PubMed  PubMed Central  Google Scholar 

  124. Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.

    Article  CAS  PubMed  Google Scholar 

  125. Alemany L, Cubilla A, Halec G, Kasamatsu E, Quirós B, Masferrer E, Tous S, Lloveras B, Hernández-Suarez G, Lonsdale R, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016;69:953–61.

    Article  PubMed  Google Scholar 

  126. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105:28–37.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RHM, Quek SC, da Silva DP, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384:2213–27.

    Article  CAS  PubMed  Google Scholar 

  128. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer. 2005;103:1258–64.

    Article  PubMed  Google Scholar 

  129. Wagenaar HC, Trimbos JB, Postema S, Anastasopoulou A, van der Geest RJ, Reiber JH, Kenter GG, Peters AA, Pattynama PM. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome for invasive cervical cancer. Gynecol Oncol. 2001;82:474–82.

    Article  CAS  PubMed  Google Scholar 

  130. Patel CN, Nazir SA, Khan Z, Gleeson FV, Bradley KM. 18F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol. 2011;196:1225–33.

    Article  PubMed  Google Scholar 

  131. TNM classification of malignant tumours. 8th ed: Wiley. Available online: https://www.wiley.com/en-us/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263579. Accessed on 20 Jan 2020.

  132. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):22–36.

    Article  PubMed  Google Scholar 

  133. Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, Miyatake T, Enomoto T, Kamiura S, Ogawa K, Kimura T. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol. 2012;127:114–20.

    Article  PubMed  Google Scholar 

  134. Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer. 2000;10:305–12.

    Article  PubMed  Google Scholar 

  135. Moscicki A-B, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura-Clayton KL, Farhat S, Broering JM, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364:1678–83.

    Article  PubMed  Google Scholar 

  136. Mello V, Sundstrom RK. Cancer, cervical intraepithelial neoplasia (CIN). In: StatPearls. Treasure Island: StatPearls Publishing; 2019.

    Google Scholar 

  137. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2012 ASCCP consensus guidelines conference 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1–S27.

    Article  PubMed  Google Scholar 

  138. Querleu D, Cibula D, Abu-Rustum NR. 2017 update on the Querleu–Morrow classification of radical hysterectomy. Ann Surg Oncol. 2017;24:3406–12.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Radical versus simple hysterectomy and pelvic node dissection in patients with low-risk early stage cervical cancer (SHAPE) - full text view - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT01658930.

  140. Lécuru F, Mathevet P, Querleu D, Leblanc E, Morice P, Daraï E, Marret H, Magaud L, Gillaizeau F, Chatellier G, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol. 2011;29:1686–91.

    Article  PubMed  Google Scholar 

  141. Diab Y. Sentinel lymph nodes mapping in cervical cancer a comprehensive review. Int J Gynecol Cancer. 2017;27:154–8.

    Article  PubMed  Google Scholar 

  142. Cormier B, Diaz JP, Shih K, Sampson RM, Sonoda Y, Park KJ, Alektiar K, Chi DS, Barakat RR, Abu-Rustum NR. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol. 2011;122:275–80.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Yoneda JY, Braganca JF, Sarian LO, Borba PP, Conceição JCJ, Zeferino LC. Surgical treatment of microinvasive cervical cancer: analysis of pathologic features with implications on radicality. Int J Gynecol Cancer. 2015;25:694–8.

    Article  PubMed  Google Scholar 

  144. Lanowska M, Mangler M, Spek A, Grittner U, Hasenbein K, Chiantera V, Hertel H, Schneider A, Köhler C, Speiser D. Radical vaginal trachelectomy (RVT) combined with laparoscopic lymphadenectomy: prospective study of 225 patients with early-stage cervical cancer. Int J Gynecol Cancer. 2011;21:1458–64.

    Article  PubMed  Google Scholar 

  145. Fanfani F, Landoni F, Gagliardi ML, Fagotti A, Preti E, Moruzzi MC, Monterossi G, Scambia G. Sexual and reproductive outcomes in early stage cervical cancer patients after excisional cone as a fertility-sparing surgery: an Italian experience. J Reprod Infertil. 2014;15:29–34.

    PubMed  PubMed Central  Google Scholar 

  146. Baalbergen A, Veenstra Y, Stalpers L. Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database Syst Rev. 2013:CD006248.

    Google Scholar 

  147. Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J Gynecol Oncol. 2017;28:e34.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76.

    Article  PubMed  Google Scholar 

  149. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.

    Article  CAS  PubMed  Google Scholar 

  150. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010:CD008285.

    Google Scholar 

  151. Marth C, Vulsteke C, Rubio MJ, Makker V, Braicu EI, McNeish IA, Radoslaw M, Ayhan A, Hasegawa K, Wu X, et al. 1063TiPENGOT-EN9/LEAP-001: a phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer. Ann Oncol. 2019;30

    Google Scholar 

  152. Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, Dumas I, Erickson B, Lang S, Nulens A, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77.

    Article  PubMed  Google Scholar 

  153. Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011;29:1678–85.

    Article  PubMed  Google Scholar 

  154. Takekuma M, Takahashi F, Arimoto T, Ishikawa M, Ota Y, Kagabu M, Kasamatsu T, Kanao H, Kawamura N, Kitagawa R, et al. Determination of eligibility criteria for salvage hysterectomy after definitive radiotherapy/concurrent chemoradiotherapy for residual cervical disease. JCO. 2019;37:5524.

    Article  Google Scholar 

  155. Kenter G, Greggi S, Vergote I, Katsaros D, Kobierski J, Massuger L, van Doorn HC, Landoni F, Van Der Velden J, Reed NS, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. JCO. 2019;37:5503.

    Article  Google Scholar 

  156. Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, Kerkar R, Engineer R, Tongaonkar H, Ghosh J, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36:1548–55.

    Article  CAS  PubMed  Google Scholar 

  157. Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer - Full Text View - ClinicalTrials.gov Available online: https://clinicaltrials.gov/ct2/show/NCT01566240. Accessed on 20 2020.

  158. Mileshkin LR, Narayan K, Moore KN, Rischin D, King M, Kolodziej I, Martyn J, Friedlander M, Quinn M, Small W, et al. A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174). JCO. 2014;32:TPS5632–TPS5632.

    Article  Google Scholar 

  159. Friedlander M, Grogan M. U.S. Preventative Services Task Force Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 2002;7:342–7.

    Article  PubMed  Google Scholar 

  160. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390:1654–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33:2129–35.

    Article  CAS  PubMed  Google Scholar 

  162. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Smith SC, Koh WJ. Palliative radiation therapy for gynaecological malignancies. Best Pract Res Clin Obstet Gynaecol. 2001;15:265–78.

    Article  CAS  PubMed  Google Scholar 

  164. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169–82.

    Article  PubMed  Google Scholar 

  165. Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG trial IND.184. Gynecol Oncol. 2010;116:163–7.

    Article  CAS  PubMed  Google Scholar 

  166. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562–9.

    Article  CAS  PubMed  Google Scholar 

  167. Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, et al. The MITO CERV-2 trial: a randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019;153:535–40.

    Article  CAS  PubMed  Google Scholar 

  168. Naumann RW, Hollebecque A, Meyer T, Devlin M-J, Oaknin A, Kerger J, López-Picazo JM, Machiels J-P, Delord J-P, Evans TRJ, et al. Safety and efficacy of Nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019;37:2825–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Chung HC, Ros W, Delord J-P, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, et al. Efficacy and safety of Pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470–8.

    Article  CAS  PubMed  Google Scholar 

  170. Minion LE, Tewari KS. Cervical cancer - state of the science: from angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018;148:609–21.

    Article  PubMed  PubMed Central  Google Scholar 

  171. Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M. Gynecology Cancer Disease Site Group follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol. 2009;114:528–35.

    Article  PubMed  Google Scholar 

  172. Salani R, Backes FJ, Fung MFK, Holschneider CH, Parker LP, Bristow RE, Goff BA. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204:466–78.

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Lorena Incorvaia and Luisa Castellana should be considered equally co-first authors.

Authors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Luisa Castellana

  2. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

  3. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Lavinia Insalaco

  4. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Giuseppa Maltese

  5. Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy

    Domenica Lorusso

  6. Università Cattolica del Sacro Cuore, Rome, Italy

    Domenica Lorusso

Authors
  1. Lorena Incorvaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luisa Castellana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lavinia Insalaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppa Maltese
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Domenica Lorusso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorena Incorvaia .

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Russo

  2. Oncology Department, University of Antwerp, Edegem, Belgium

    Marc Peeters

  3. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

  4. Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & Icahn School of Medicine, Mount Sinai, NY, USA

    Christian Rolfo

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Incorvaia, L., Castellana, L., Insalaco, L., Maltese, G., Lorusso, D. (2021). Endometrial and Cervical Cancers. In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_53

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56051-5_53

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56050-8

  • Online ISBN: 978-3-030-56051-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation